With all these failed treatments including convalescent blood plasma (shown by trials to have no statisticial effect), Remdesivir (see WHO), Dexamethasone (see https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/fulltext for concerns), Ibuprofren(!), hydroxychloroquine and azithromycin , Yet not a word about Mesoblast's Remi-L ??? the only one left in the race and last chance to save thousands of lives or 50-60% of covid-19 deaths , not a word out there shorts ?? what's worse is those trials were delaying our trial taking potential suitable patients that may have died in the process , the answer will drop soon enough .
Elli Lilly and now Regeneron not treating advanced COIVD-19 sufferers, page-21
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |